Search

Your search keyword '"Zigeuner R"' showing total 771 results
Start Over Author "Zigeuner R"
771 results on '"Zigeuner R"'

1. Individual patient data validation of the definitions of BCG failure in patients with non-muscle invasive urothelial carcinoma of the bladder: An international multi-centre retrospective study

Author

Gontero, P., primary, Soria, F., additional, Babjuk, M., additional, Burger, M., additional, Comperat, E., additional, Mostafid, H., additional, Palou Redorta, J., additional, Roupret, M., additional, Van Rhijn, B.W., additional, Zigeuner, R., additional, Shariat, S.F., additional, Cohen, D., additional, Masson-Lecomte, A., additional, Xylinas, E., additional, Mariappan, P., additional, Rai, B.P., additional, Capoun, O., additional, Soukup, V., additional, Thalmann, G., additional, Pradere, B., additional, Seisen, T., additional, Dominguez-Escrig, J.L., additional, Liedberg, F., additional, and Sylvester, R.J., additional

Published
2024
Full Text
View/download PDF

2. Towards defining follow-up strategies for patients with primary (first diagnosis) EAU2021 intermediate-risk non-muscle invasive bladder cancer

Author

Contieri, R., primary, Beijert, I., additional, Martini, A., additional, Camperat, E.M., additional, Hernandez, V., additional, Bruins, H.M., additional, Dominguez-Escrig, J.L., additional, Liedberg, F., additional, Masson-Lecomte, A., additional, Cohen, D., additional, Mostafid, H., additional, Shariat, S.F., additional, Roupret, M., additional, Pradere, B., additional, Zigeuner, R., additional, Soria, F., additional, Soukup, V., additional, Palou Redorta, J., additional, Capoun, O., additional, Burger, M., additional, Gontero, P., additional, Sylvester, R., additional, Mertens, L., additional, and Van Rhijn, B.W.G., additional

Published
2024
Full Text
View/download PDF

3. Charlson-Deyo Comorbidity Index as a novel predictor for recurrence in non-muscle invasive bladder cancer

Author

Scheipner, L., primary, Zurl, H., additional, Altziebler, J.V., additional, Pichler, G.P., additional, Schöpfer-Schwab, S., additional, Jasarevic, S., additional, Gaisl, M., additional, Pohl, K.C., additional, Pemberger, K., additional, Andlar, S., additional, Hutterer, G.C., additional, Bele, U., additional, Leitsmann, C., additional, Leitsmann, M., additional, Augustin, H., additional, Zigeuner, R., additional, Ahyai, S., additional, and Mischinger, J., additional

Published
2024
Full Text
View/download PDF

4. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees

Author

Horwich, A., Babjuk, M., Bellmunt, J., Bruins, H.M., De Reijke, T.M., De Santis, M., Gillessen, S., James, N., Maclennan, S., Palou, J., Powles, T., Ribal, M.J., Shariat, S.F., Van Der Kwast, T., Xylinas, E., Agarwal, N., Arends, T., Bamias, A., Birtle, A., Black, P.C., Bochner, B.H., Bolla, M., Boormans, J.L., Bossi, A., Briganti, A., Brummelhuis, I., Burger, M., Castellano, D., Cathomas, R., Chiti, A., Choudhury, A., Compérat, E., Crabb, S., Culine, S., De Bari, B., DeBlok, W., De Visschere, P.J.L., Decaestecker, K., Dimitropoulos, K., Dominguez-Escrig, J.L., Fanti, S., Fonteyne, V., Frydenberg, M., Futterer, J.J., Gakis, G., Geavlete, B., Gontero, P., Grubmüller, B., Hafeez, S., Hansel, D.E., Hartmann, A., Hayne, D., Henry, A.M., Hernandez, V., Herr, H., Herrmann, K., Hoskin, P., Huguet, J., Jereczek-Fossa, B.A., Jones, R., Kamat, A.M., Khoo, V., Kiltie, A.E., Krege, S., Ladoire, S., Lara, P.C., Leliveld, A., Linares-Espinós, E., Løgager, V., Lorch, A., Loriot, Y., Meijer, R., Carmen Mir, M., Moschini, M., Mostafid, H., Müller, A.-C., Müller, C.R., N’Dow, J., Necchi, A., Neuzillet, Y., Oddens, J.R., Oldenburg, J., Osanto, S., Oyen, W.J.G., Pacheco-Figueiredo, L., Pappot, H., Patel, M.I., Pieters, B.R., Plass, K., Remzi, M., Retz, M., Richenberg, J., Rink, M., Roghmann, F., Rosenberg, J.E., Rouprêt, M., Rouvière, O., Salembier, C., Salminen, A., Sargos, P., Sengupta, S., Sherif, A., Smeenk, R.J., Smits, A., Stenzl, A., Thalmann, G.N., Tombal, B., Turkbey, B., Vahr Lauridsen, S., Valdagni, R., Van Der Heijden, A.G., Van Poppel, H., Vartolomei, M.D., Veskimäe, E., Vilaseca, A., Vives Rivera, F.A., Wiegel, T., Wiklund, P., Williams, A., Zigeuner, R., and Witjes, J.A.

Published
2019
Full Text
View/download PDF

5. Evaluierung der Wertigkeit der präoperativen Neutrophilen-/Lymphozyten-Ratio als Prognosefaktor bezüglich des krebsspezifischen-, metastasenfreien- und Gesamtüberlebens von Nierenzellkarzinompatienten in einer europäischen Single-Center Serie [Poster]

Author

Jesche, J, Hutterer, GC, Pichler, M, Stoeckigt, C, Chromecki, TF, Stojakovic, T, Golbeck, S, Gerger, A, Pummer, K, and Zigeuner, R

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Fragestellung: Die Neutrophilen-/Lymphozyten Ratio (NLR) wurde wiederholt als Indikator systemischer Inflammation beschrieben, wobei Daten vorangehender Studien widersprüchliche Resultate bezüglich seiner unabhängigen prognostischen Wertigkeit bei nicht-metastasierten Nierenzellkarzinompatienten[for full text, please go to the a.m. URL], 39. Gemeinsame Tagung der Österreichischen Gesellschaft für Urologie und Andrologie sowie der Bayerischen Urologenvereinigung

Published
2023

9. Prognosis of Primary Papillary Ta Grade 3 Bladder Cancer in the Non-muscle-invasive Spectrum

Author

Beijert, I.J., Hentschel, A.E., Bründl, J., Compérat, E.M., Plass, K., Rodríguez, O., Subiela Henríquez, J.D., Hernández, V., Peña, E. de la, Alemany, I., Turturica, D., Pisano, F., Soria, F., Čapoun, O., Bauerová, L., Pešl, M., Bruins, H.M., Runneboom, W., Herdegen, S., Breyer, J., Brisuda, A., Calatrava, A., Rubio-Briones, J., Seles, M., Mannweiler, S., Bosschieter, J., Kusuma, V.R.M., Ashabere, D., Huebner, N., Cotte, J., Mertens, L.S., Claps, F., Masson-Lecomte, A., Liedberg, F., Cohen, D., Lunelli, L., Cussenot, O., Sheikh, S., Volanis, D., Côté, J.F., Rouprêt, M., Haitel, A., Shariat, S.F., Mostafid, A.H., Nieuwenhuijzen, J.A., Zigeuner, R., Dominguez-Escrig, J.L., Hacek, J., Zlotta, A.R., Burger, M., Evert, M., Hulsbergen-van de Kaa, C.A., Heijden, A.G. van der, Kiemeney, L.A.L.M., Soukup, V., Molinaro, L., Gontero, P., Llorente, C., Algaba, F., Palou, J., N'Dow, J., Ribal, M.J., Kwast, T.H. van der, Babjuk, M., Sylvester, R.J., Rhijn, B.W.G. van, Beijert, I.J., Hentschel, A.E., Bründl, J., Compérat, E.M., Plass, K., Rodríguez, O., Subiela Henríquez, J.D., Hernández, V., Peña, E. de la, Alemany, I., Turturica, D., Pisano, F., Soria, F., Čapoun, O., Bauerová, L., Pešl, M., Bruins, H.M., Runneboom, W., Herdegen, S., Breyer, J., Brisuda, A., Calatrava, A., Rubio-Briones, J., Seles, M., Mannweiler, S., Bosschieter, J., Kusuma, V.R.M., Ashabere, D., Huebner, N., Cotte, J., Mertens, L.S., Claps, F., Masson-Lecomte, A., Liedberg, F., Cohen, D., Lunelli, L., Cussenot, O., Sheikh, S., Volanis, D., Côté, J.F., Rouprêt, M., Haitel, A., Shariat, S.F., Mostafid, A.H., Nieuwenhuijzen, J.A., Zigeuner, R., Dominguez-Escrig, J.L., Hacek, J., Zlotta, A.R., Burger, M., Evert, M., Hulsbergen-van de Kaa, C.A., Heijden, A.G. van der, Kiemeney, L.A.L.M., Soukup, V., Molinaro, L., Gontero, P., Llorente, C., Algaba, F., Palou, J., N'Dow, J., Ribal, M.J., Kwast, T.H. van der, Babjuk, M., Sylvester, R.J., and Rhijn, B.W.G. van

Abstract

Contains fulltext : 294430.pdf (Publisher’s version ) (Open Access), BACKGROUND: Ta grade 3 (G3) non-muscle-invasive bladder cancer (NMIBC) is a relatively rare diagnosis with an ambiguous character owing to the presence of an aggressive G3 component together with the lower malignant potential of the Ta component. The European Association of Urology (EAU) NMIBC guidelines recently changed the risk stratification for Ta G3 from high risk to intermediate, high, or very high risk. However, prognostic studies on Ta G3 carcinomas are limited and inconclusive. OBJECTIVE: To evaluate the prognostic value of categorizing Ta G3 compared to Ta G2 and T1 G3 carcinomas. DESIGN, SETTING, AND PARTICIPANTS: Individual patient data for 5170 primary Ta-T1 bladder tumors from 17 hospitals were analyzed. Transurethral resection of the tumor was performed between 1990 and 2018. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Time to recurrence and time to progression were analyzed using cumulative incidence functions, log-rank tests, and multivariable Cox-regression models with interaction terms stratified by institution. RESULTS AND LIMITATIONS: Ta G3 represented 7.5% (387/5170) of Ta-T1 carcinomas of which 42% were classified as intermediate risk. Time to recurrence did not differ between Ta G3 and Ta G2 (p = 0.9) or T1 G3 (p = 0.4). Progression at 5 yr occurred for 3.6% (95% confidence interval [CI] 2.7-4.8%) of Ta G2, 13% (95% CI 9.3-17%) of Ta G3, and 20% (95% CI 17-23%) of T1 G3 carcinomas. Time to progression for Ta G3 was shorter than for Ta G2 (p < 0.001) and longer than for T1 G3 (p = 0.002). Patients with Ta G3 NMIBC with concomitant carcinoma in situ (CIS) had worse prognosis and a similar time to progression as for patients with T1 G3 NMIBC with CIS (p = 0.5). Multivariable analyses for recurrence and progression showed similar results. CONCLUSIONS: The prognosis of Ta G3 tumors in terms of progression appears to be in between that of Ta G2 and T1 G3. However, patients with Ta G3 NMIBC with concomitant CIS have worse prognosis that is compar

Published
2023

11. Nierenzellkarzinom-Patienten ≥80 Jahren haben eine signifikant höhere krebsspezifische und nicht-krebsspezifische Mortalität nach operativer Therapie als Patienten im typischen Erstdiagnosealter zwischen 60 und 70 Jahren – Ergebnisse einer komparativen Analyse dieser Altersgruppen unter Integration von Competing-Risks-Analysen [Poster]

Author

Brookman-May, S.D., Zigeuner, R., Sountoulides, P., Truss, M., Dalpiaz, O., Wolff, I., Hoschke, B., Gilfrich, C., Pichler, Martin, Waidelich, R., Stief, C., Cindolo, L., Schips, L., and May, M.

Published
2023

13. Vergleich der Überlebenszeiten von PatientInnen mit metastasiertem Nierenzellkarzinom anhand zweier historischer Vergleichskohorten (Zytokintherapie vs. Targeted Agents) – eine europäische Single-Center Serie über 26 Jahre

Author

Strini, K.A., Hutterer, G., Golbeck, S., Mrsic, E., Krieger, D., Bezan, A., Jesche-Chromecki, J., Pummer, K., Pichler, M., and Zigeuner, R.

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Fragestellung: Durch die Zulassung von ‚Targeted Agents’ 2006, erfuhr die Therapie des metastasierten Nierenzellkarzinoms (mRCC) einen Paradigmenwechsel, da sich vielfach in klinischen Studien ein signifikant verbessertes progressionsfreies Überleben (PFS) zeigte. Da es dabei oftmals[for full text, please go to the a.m. URL], 41. Gemeinsame Tagung der Österreichischen Gesellschaft für Urologie und Andrologie und der Bayerischen Urologenvereinigung

Published
2023

14. Validierung der präoperativen Thrombozyten-Lymphozyten- Ratio (PLR) als Prognosefaktor beim Urothelkarzinom des oberen Harntraktes in einer europäischen Single-Center-Serie [Abstract]

Author

Jesche-Chromecki, J., Hutterer, G.C., Dalpiaz, O., Mrsic, E., Krieger, D., Bezan, A., Stojakovic, T., Pummer, K., Zigeuner, R., and Pichler, M.

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Fragestellung: Die Thrombozyten-Lymphozyten-Ratio (PLR) als Indikator systemischer Inflammation wurde wiederholt bei verschiedenen humanen Tumorentitäten als prognostisch relevant beschrieben. Wir untersuchten die potentielle prognostische Wertigkeit der präoperativen PLR in einer europäischen[for full text, please go to the a.m. URL], 41. Gemeinsame Tagung der Österreichischen Gesellschaft für Urologie und Andrologie und der Bayerischen Urologenvereinigung

Published
2023

15. Die prognostische Relevanz von Leukozytose, Thrombozytose und Anämie bei PatientInnen mit nicht-metastasiertem Nierenzellkarzinom

Author

Krieger, D, Mrsic, E, Bezan, A, Stojakovic, T, Pummer, K, Zigeuner, R, Pichler, M, and Hutterer, GC

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Fragestellung: Inflammatorische Laborparameter wie Differentialblutbild, Leukozyten- und Thrombozytenzahl können durch ein Tumorgeschehen verschiedenartig beeinflusst werden. Ziel dieser Studie ist die Untersuchung einer möglichen Korrelation zwischen den präoperativ erhobenen inflammatorischen[for full text, please go to the a.m. URL], 41. Gemeinsame Tagung der Österreichischen Gesellschaft für Urologie und Andrologie und der Bayerischen Urologenvereinigung

Published
2023

16. Prognostische Bedeutung klinischer und histopathologischer Parameter hinsichtlich des Gesamtüberlebens beim Nierenzellkarzinom – Langzeitanalyse eines europäischen Single-Centers 1984-2013

Author

Seles, M, Strini, KA, Pohlmann, K, Bezan, A, Pummer, K, Pichler, M, Zigeuner, R, and Hutterer, GC

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Fragestellung: Die vorgestellte Arbeit soll die Bedeutung verschiedener klinischer und histopathologischer Parameter bei PatientintInnen mit Nierenzellkarzinom in Zusammenschau mit dem histologischen Subtyp in Hinblick auf das Gesamtüberleben nach operativer Sanierung beantworten. Methodik: [zum vollständigen Text gelangen Sie über die oben angegebene URL], 42. Gemeinsame Tagung der Bayerischen Urologenvereinigung und der Österreichischen Gesellschaft für Urologie und Andrologie

Published
2023

19. MRT gezielte Fusionsbiopsie der Prostata vs. systematische transrektale ultraschallgezielte Biopsie vs. kombiniertes Biopsieverfahren zur Detektion und korrekten Klassifikation des Prostatakarzinoms: eine retrospektive Kohortenstudie

Author

Mischinger, J, Schöllnast, H, Zurl, H, Geyer, M, Fischereder, K, Adelsmayr, G, Igrec, J, Fritz, GA, Merdzo-Hörmann, M, Elstner, J, Schmid, J, Triebl, A, Trimmel, V, Reiter, C, Steiner, J, Rosenlechner, D, Seles, M, Pichler, G, Pichler, M, Riedl, JM, Schöpfer-Schwab, S, Strobl, J, Hutterer, G, Zigeuner, R, Pummer, K, Augustin, H, Ahyai, S, Mannweiler, S, Fuchsjäger, M, and Talakic, E

Subjects
ddc: 610, Medicine and health
Abstract

Einleitung: Ziel dieser Studie ist es, die Prostatakarzinom Detektionsrate der MRT gezielten Fusionsbiopsie (FB) mit der systematischen ultraschallgezielten Biopsie (SB) und der kombinierten Biopsie (FB+SB) bei Biopsie naiven (BN) und bei Patienten mit vorangegangener negativer Biopsie (VN) zu [zum vollständigen Text gelangen Sie über die oben angegebene URL]

Published
2023

20. Combining targeted and systematic transrectal ultrasound guided prostate biopsy to improve verifcation and reduce misclassifcation of prostate cancer

Author

Mischinger, J., Schoellnast, H., Zurl, H., Geyer, M., Fischereder, K., Scheipner, L., Jasarevic, S., Adelsmayr, F., Igrec, J., Fritz, G., Merdzo-Hörmann, M., Elstner, J., Schmid, J., Triebl, A., Reiter, C., Steiner, J., Rosenlechner, D., Seles, M., Pichler, G., Pichler, Martin, Riedl, J., Schöpfer-Schwab, S., Hutterer, G., Zigeuner, R., Augustin, H., Ahyai, S., Mannweiler, S., Fuchsjäger, M., and Talakic, E.

Published
2023

21. Prognostic significance of Fuhrman grade and age for cancer-specific and overall survival in patients with papillary renal cell carcinoma: results of an international multi-institutional study on 2189 patients

Author

Borgmann, H., Musquera, M., Haferkamp, A., Vilaseca, A., Klatte, T., Shariat, S. F., Scavuzzo, A., Jimenez Rios, M. A., Wolff, I., Capitanio, U., Dell’Oglio, P., Krabbe, L. M., Herrmann, E., Ecke, T., Vergho, D., Huck, N., Wagener, N., Pahernik, S., Zastrow, S., Wirth, M., Surcel, C., Mirvald, C., Prochazkova, K., Hutterer, G., Zigeuner, R., Cindolo, L., Hora, M., Stief, C. G., May, M., and Brookman-May, S. D.

Published
2017
Full Text
View/download PDF

22. Prognosis of primary papillary Ta-G3 bladder cancer in the non-muscle invasive spectrum

Author

Beijert, I.J., primary, Hentschel, A.E., additional, Bründl, J., additional, Compérat, E.M, additional, Plass, K., additional, Rodríguez, O., additional, Subiela Henríquez, J.D., additional, Hernández, V., additional, De La Peña, E., additional, Alemany, I., additional, Turturica, D., additional, Pisano, F., additional, Soria, F., additional, Čapoun, O., additional, Bauerová, L., additional, Pešl, M., additional, Bruins, H.M., additional, Runneboom, W., additional, Herdegen, S., additional, Breyer, J., additional, Brisuda, A., additional, Calatrava, A., additional, Rubio-Briones, J.., additional, Seles, M., additional, Mannweiler, S., additional, Bosschieter, J., additional, Kusuma, V.R.M., additional, Ashabere, D., additional, Huebner, N., additional, Cotte, J., additional, Mertens, L.S, additional, Masson-Lecomte, A., additional, Liedberg, F., additional, Cohen, D., additional, Lunelli, L., additional, Cussenot, O., additional, El Sheikh, S., additional, Volanis, D., additional, Côté, J., additional, Rouprêt, M., additional, Haitel, A., additional, Shariat, S.F., additional, Mostafid, A.H., additional, Nieuwenhuijzen, J.A., additional, Zigeuner, R., additional, Dominguez-Escrig, J.L., additional, Hacek, J., additional, Zlotta, A.R., additional, Burger, M., additional, Evert, M., additional, Hulsbergen - Van De Kaa, C.A., additional, Van Der Heijden, A.G., additional, Kiemeney, L.A.L.M., additional, Soukup, V., additional, Molinaro, L., additional, Gontero, P., additional, Llorente, C., additional, Algaba, F., additional, Palou, J., additional, N’Dow, J., additional, Ribal, M.J., additional, Van Der Kwast, T.H., additional, Babjuk, M., additional, Sylvester, R.J., additional, and Van Rhijn, B.W.G., additional

Published
2022
Full Text
View/download PDF

23. Influence of perioperative administration, transfusion volume and storage age of red blood cell concentrates on clinical outcomes in non-metastatic renal cell carcinoma patients

Author

Barth, D.A., primary, Sareban, N., additional, Lindner, A.K., additional, Daller, L.A.J., additional, Matzhold, E.M., additional, Hutterer, G.C., additional, Smolle, M.A., additional, Riedl, J.M., additional, Huemer, M., additional, Mannweiler, S., additional, Jost, P.J., additional, Bauernhofer, T., additional, Ahyai, S., additional, Zigeuner, R., additional, Pichler, R., additional, and Pichler, M., additional

Published
2022
Full Text
View/download PDF

24. O3 - Prognosis of primary papillary Ta-G3 bladder cancer in the non-muscle invasive spectrum

Author

Beijert, I.J., Hentschel, A.E., Bründl, J., Compérat, E.M, Plass, K., Rodríguez, O., Subiela Henríquez, J.D., Hernández, V., De La Peña, E., Alemany, I., Turturica, D., Pisano, F., Soria, F., Čapoun, O., Bauerová, L., Pešl, M., Bruins, H.M., Runneboom, W., Herdegen, S., Breyer, J., Brisuda, A., Calatrava, A., Rubio-Briones, J.., Seles, M., Mannweiler, S., Bosschieter, J., Kusuma, V.R.M., Ashabere, D., Huebner, N., Cotte, J., Mertens, L.S, Masson-Lecomte, A., Liedberg, F., Cohen, D., Lunelli, L., Cussenot, O., El Sheikh, S., Volanis, D., Côté, J., Rouprêt, M., Haitel, A., Shariat, S.F., Mostafid, A.H., Nieuwenhuijzen, J.A., Zigeuner, R., Dominguez-Escrig, J.L., Hacek, J., Zlotta, A.R., Burger, M., Evert, M., Hulsbergen - Van De Kaa, C.A., Van Der Heijden, A.G., Kiemeney, L.A.L.M., Soukup, V., Molinaro, L., Gontero, P., Llorente, C., Algaba, F., Palou, J., N’Dow, J., Ribal, M.J., Van Der Kwast, T.H., Babjuk, M., Sylvester, R.J., and Van Rhijn, B.W.G.

Published
2022
Full Text
View/download PDF

26. Validierung zweier Subklassifikationsmethoden des pT1 Urothelkarzinoms der Harnblase sowie Evaluierung ihrer prognostischen Relevanz

Author

Schöpfer-Schwab, S, Gleissner, J, Hutterer, G, Leoni, M, Mannweiler, S, Pummer, K, Zigeuner, R, Geyer, M, Pichler, G, Seles, M, Zurl, H, and Mischinger, J

Subjects
ddc: 610, Medicine and health
Abstract

Einleitung: Die Therapiewahl beim High-risk-pT1-Blasenkarzinom (BC) stellt aufgrund fehlender validierter Subklassifizierungssysteme bisher eine Herausforderung dar. Ziel dieser Arbeit ist die Validierung der T1m/T1e- bzw. ROL-Subklassifizierung und die Evaluierung ihrer prognostischen Relevanz [zum vollständigen Text gelangen Sie über die oben angegebene URL]

Published
2022
Full Text
View/download PDF

27. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer

Author

Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Van der Kwast T, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Comperat E, Crabb S, Culine S, De Bari B, De Blok W, De Visschere PJL, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmuller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinos E, Logager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Muller AC, Muller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, Oyen WJG, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Roupret M, Rouviere O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Van der Heijden AG, Van Poppel H, Vartolomei MD, Veskimae E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Zigeuner R, Horwich A, Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Der Kwast TV, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, De Bari B, De Blok W, J L De Visschere P, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Müller AC, Müller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, J G Oyen W, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Der Heijden AGV, Van Poppel H, Vartolomei MD, Veskimäe E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Zigeuner R, Horwich A., UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service d'urologie, Witjes, Ja, Babjuk, M, Bellmunt, J, Bruins, Hm, De Reijke, Tm, De Santis, M, Gillessen, S, James, N, Maclennan, S, Palou, J, Powles, T, Ribal, Mj, Shariat, Sf, Van der Kwast, T, Xylinas, E, Agarwal, N, Arends, T, Bamias, A, Birtle, A, Black, Pc, Bochner, Bh, Bolla, M, Boormans, Jl, Bossi, A, Briganti, A, Brummelhuis, I, Burger, M, Castellano, D, Cathomas, R, Chiti, A, Choudhury, A, Comperat, E, Crabb, S, Culine, S, De Bari, B, De Blok, W, De Visschere, Pjl, Decaestecker, K, Dimitropoulos, K, Dominguez-Escrig, Jl, Fanti, S, Fonteyne, V, Frydenberg, M, Futterer, Jj, Gakis, G, Geavlete, B, Gontero, P, Grubmuller, B, Hafeez, S, Hansel, De, Hartmann, A, Hayne, D, Henry, Am, Hernandez, V, Herr, H, Herrmann, K, Hoskin, P, Huguet, J, Jereczek-Fossa, Ba, Jones, R, Kamat, Am, Khoo, V, Kiltie, Ae, Krege, S, Ladoire, S, Lara, Pc, Leliveld, A, Linares-Espinos, E, Logager, V, Lorch, A, Loriot, Y, Meijer, R, Mir, Mc, Moschini, M, Mostafid, H, Muller, Ac, Muller, Cr, N'Dow, J, Necchi, A, Neuzillet, Y, Oddens, Jr, Oldenburg, J, Osanto, S, Oyen, Wjg, Pacheco-Figueiredo, L, Pappot, H, Patel, Mi, Pieters, Br, Plass, K, Remzi, M, Retz, M, Richenberg, J, Rink, M, Roghmann, F, Rosenberg, Je, Roupret, M, Rouviere, O, Salembier, C, Salminen, A, Sargos, P, Sengupta, S, Sherif, A, Smeenk, Rj, Smits, A, Stenzl, A, Thalmann, Gn, Tombal, B, Turkbey, B, Lauridsen, Sv, Valdagni, R, Van der Heijden, Ag, Van Poppel, H, Vartolomei, Md, Veskimae, E, Vilaseca, A, Rivera, Fav, Wiegel, T, Wiklund, P, Williams, A, Zigeuner, R, and Horwich, A

Subjects
Treatment, Consensus, Follow-up, education, Bladder cancer, Diagnosis, Consensu, Delphi, Diagnosi
Abstract

Background: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial.Objective: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management.Design: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts prior to voting during a consensus conference.Setting: Online Delphi survey and consensus conference.Participants: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management.Outcome measurements and statistical analysis: Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), and 7-9 (agree). A priori (level 1) consensus was defined as >= 70% agreement and

Published
2020

28. MRT gezielte Fusionsbiopsie der Prostata vs. systematische transrektale ultraschallgezielte Biopsie vs. kombiniertes Biopsieverfahren zur Detektion und korrekten Klassifikation des Prostatakarzinoms: Eine retrospektive Kohortenstudie

Author

Mischinger, J, Schöllnast, H, Zurl, H, Geyer, M, Fischereder, K, Adelsmayr, G, Igrec, J, Fritz, GA, Merdzo-Hörmann, M, Elstner, J, Schmid, J, Triebl, A, Trimmel, V, Reiter, C, Steiner, J, Rosenlechner, D, Seles, M, Pichler, G, Pichler, M, Riedl, JM, Schöpfer-Schwab, S, Strobl, J, Hutterer, G, Zigeuner, R, Pummer, K, Augustin, H, Ahyai, S, Mannweiler, S, Fuchsjäger, M, Talakic, E, Mischinger, J, Schöllnast, H, Zurl, H, Geyer, M, Fischereder, K, Adelsmayr, G, Igrec, J, Fritz, GA, Merdzo-Hörmann, M, Elstner, J, Schmid, J, Triebl, A, Trimmel, V, Reiter, C, Steiner, J, Rosenlechner, D, Seles, M, Pichler, G, Pichler, M, Riedl, JM, Schöpfer-Schwab, S, Strobl, J, Hutterer, G, Zigeuner, R, Pummer, K, Augustin, H, Ahyai, S, Mannweiler, S, Fuchsjäger, M, and Talakic, E

Published
2022

29. T1G1 Bladder Cancer: Prognosis for this Rare Pathological Diagnosis Within the Non-muscle-invasive Bladder Cancer Spectrum

Author

Beijert, I.J., Hentschel, A.E., Bründl, J., Compérat, E.M., Plass, K., Rodríguez, O., Henríquez, J.D. Subiela, Hernández, V., Peña, E. de la, Alemany, I., Turturica, D., Pisano, F., Soria, F., Čapoun, O., Bauerová, L., Pešl, M., Bruins, H.M., Runneboom, W., Herdegen, S., Breyer, J., Brisuda, A., Calatrava, A., Rubio-Briones, J., Seles, M., Mannweiler, S., Bosschieter, J., Kusuma, V.R.M., Ashabere, D., Huebner, N., Cotte, J., Mertens, L.S., Masson-Lecomte, A., Liedberg, F., Cohen, D., Lunelli, L., Cussenot, O., Sheikh, S., Volanis, D., Côté, J.F., Rouprêt, M., Haitel, A., Shariat, S.F., Mostafid, A.H., Nieuwenhuijzen, J.A., Zigeuner, R., Dominguez-Escrig, J.L., Hacek, J., Zlotta, A.R., Burger, M., Evert, M., Hulsbergen-van de Kaa, C.A., Heijden, A.G. van der, Kiemeney, L.A.L.M., Soukup, V., Molinaro, L., Gontero, P., Llorente, C., Algaba, F., Palou, J., N'Dow, J., Ribal, M.J., Kwast, Theodorus H. van der, Babjuk, M., Sylvester, R.J., Rhijn, B.W. van, Beijert, I.J., Hentschel, A.E., Bründl, J., Compérat, E.M., Plass, K., Rodríguez, O., Henríquez, J.D. Subiela, Hernández, V., Peña, E. de la, Alemany, I., Turturica, D., Pisano, F., Soria, F., Čapoun, O., Bauerová, L., Pešl, M., Bruins, H.M., Runneboom, W., Herdegen, S., Breyer, J., Brisuda, A., Calatrava, A., Rubio-Briones, J., Seles, M., Mannweiler, S., Bosschieter, J., Kusuma, V.R.M., Ashabere, D., Huebner, N., Cotte, J., Mertens, L.S., Masson-Lecomte, A., Liedberg, F., Cohen, D., Lunelli, L., Cussenot, O., Sheikh, S., Volanis, D., Côté, J.F., Rouprêt, M., Haitel, A., Shariat, S.F., Mostafid, A.H., Nieuwenhuijzen, J.A., Zigeuner, R., Dominguez-Escrig, J.L., Hacek, J., Zlotta, A.R., Burger, M., Evert, M., Hulsbergen-van de Kaa, C.A., Heijden, A.G. van der, Kiemeney, L.A.L.M., Soukup, V., Molinaro, L., Gontero, P., Llorente, C., Algaba, F., Palou, J., N'Dow, J., Ribal, M.J., Kwast, Theodorus H. van der, Babjuk, M., Sylvester, R.J., and Rhijn, B.W. van

Abstract

Item does not contain fulltext, BACKGROUND: The pathological existence and clinical consequence of stage T1 grade 1 (T1G1) bladder cancer are the subject of debate. Even though the diagnosis of T1G1 is controversial, several reports have consistently found a prevalence of 2-6% G1 in their T1 series. However, it remains unclear if T1G1 carcinomas have added value as a separate category to predict prognosis within the non-muscle-invasive bladder cancer (NMIBC) spectrum. OBJECTIVE: To evaluate the prognostic value of T1G1 carcinomas compared to TaG1 and T1G2 carcinomas within the NMIBC spectrum. DESIGN, SETTING, AND PARTICIPANTS: Individual patient data for 5170 primary Ta and T1 bladder tumors from 17 hospitals in Europe and Canada were analyzed. Transurethral resection (TUR) was performed between 1990 and 2018. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Time to recurrence and progression were analyzed using cumulative incidence functions, log-rank tests, and multivariable Cox regression models stratified by institution. RESULTS AND LIMITATIONS: T1G1 represented 1.9% (99/5170) of all carcinomas and 5.3% (99/1859) of T1 carcinomas. According to primary TUR dates, the proportion of T1G1 varied between 0.9% and 3.5% per year, with similar percentages in the early and later calendar years. We found no difference in time to recurrence between T1G1 and TaG1 (p = 0.91) or between T1G1 and T1G2 (p = 0.30). Time to progression significantly differed between TaG1 and T1G1 (p < 0.001) but not between T1G1 and T1G2 (p = 0.30). Multivariable analyses for recurrence and progression showed similar results. CONCLUSIONS: The relative prevalence of T1G1 diagnosis was low and remained constant over the past three decades. Time to recurrence of T1G1 NMIBC was comparable to that for other stage/grade NMIBC combinations. Time to progression of T1G1 NMIBC was comparable to that for T1G2 but not for TaG1, suggesting that treatment and surveillance of T1G1 carcinomas should be more like the approaches for T1G2 NMIBC in

Published
2022

31. Collecting System Invasion and Fuhrman Grade But Not Tumor Size Facilitate Prognostic Stratification of Patients With pT2 Renal Cell Carcinoma

Author

Brookman-May, S., May, M., Zigeuner, R., Shariat, S.F., Scherr, D.S., Chromecki, T., Moch, H., Wild, P.J., Mohamad-Al-Ali, B., Cindolo, L., Wieland, W.F., Schips, L., De Cobelli, O., Rocco, B., Santoro, L., De Nunzio, C., Tubaro, A., Coman, I., Feciche, B., Truss, M., Dalpiaz, O., Hohenfellner, M., Gilfrich, C., Wirth, M.P., Burger, M., and Pahernik, S.

Published
2011
Full Text
View/download PDF

32. Die postoperative Prognose des chromophoben Nierenzellkarzinoms: Eine vergleichende Analyse anhand der multinationalen CORONA-Datenbank

Author

May, M., Zigeuner, R., Aziz, A., Cindolo, L., Gilfrich, C., Schips, L., De Cobelli, O., Rocco, B., De Nunzio, C., Tubaro, A., Coman, I., Feciche, B., Truss, M., Hoschke, B., Dalpiaz, O., Stoltze, A., Fenske, F., Fritsche, H.-M., Chromecki, T., Lebentrau, S., Figenshau, R.S., Madison, K., Sánchez-Chapado, M., del Carmen Santiago Martin, M., Salzano, L., Lotrecchiano, G., Joniau, S., Waidelich, R., Stief, C.G., Brookman-May, S., and Mitglieder des „CORONA projects“ und/oder der Projektgruppe „Young Academic Urologists Renal Cancer Group“ der European Association of Urology (EAU)

Published
2014
Full Text
View/download PDF

33. Real-world evidence for interobserver-agreement of PI-RADS-version-2 and the value of combining 4-core-targeted-MRI-TRUS-fusion and systematic-12-core-TRUS prostate biopsy for the diagnosis of prostate cancer according to biopsy-history

Author

Mischinger, J., primary, Schöllnast, H., additional, Zurl, H., additional, Geyer, M., additional, Fischereder, K., additional, Adelsmayr, G., additional, Igrec, J., additional, Fritz, G., additional, Merdzo-Hörmann, M., additional, Elster, J., additional, Schmid, J., additional, Triebl, A., additional, Trimmel, V., additional, Rosenlechner, D., additional, Seles, M., additional, Pichler, G.P., additional, Schöpfer-Schwab, S., additional, Strobl, J., additional, Hutterer, G.C., additional, Zigeuner, R., additional, Pummer, K., additional, Augustin, H., additional, Mannweiler, S., additional, Fuchsjäger, M., additional, and Talakic, E., additional

Published
2021
Full Text
View/download PDF

36. Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study

Author

Rhijn, B.W. van, Hentschel, A.E., Bründl, J., Compérat, E.M., Hernández, V., Čapoun, O., Bruins, H.M., Cohen, D., Rouprêt, M., Shariat, S.F., Mostafid, A.H., Zigeuner, R., Dominguez-Escrig, J.L., Burger, M., Soukup, V., Gontero, P., Palou, J., Kwast, Theodorus H. van der, Heijden, A.G. van der, Kiemeney, L.A., Babjuk, M., Sylvester, R.J., Rhijn, B.W. van, Hentschel, A.E., Bründl, J., Compérat, E.M., Hernández, V., Čapoun, O., Bruins, H.M., Cohen, D., Rouprêt, M., Shariat, S.F., Mostafid, A.H., Zigeuner, R., Dominguez-Escrig, J.L., Burger, M., Soukup, V., Gontero, P., Palou, J., Kwast, Theodorus H. van der, Heijden, A.G. van der, Kiemeney, L.A., Babjuk, M., and Sylvester, R.J.

Abstract

Item does not contain fulltext, BACKGROUND: In the current European Association of Urology (EAU) non-muscle-invasive bladder cancer (NMIBC) guideline, two classification systems for grade are advocated: WHO1973 and WHO2004/2016. OBJECTIVE: To compare the prognostic value of these WHO systems. DESIGN, SETTING, AND PARTICIPANTS: Individual patient data for 5145 primary Ta/T1 NMIBC patients from 17 centers were collected between 1990 and 2019. The median follow-up was 3.9 yr. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Univariate and multivariable analyses of WHO1973 and WHO2004/2016 stratified by center were performed for time to recurrence, progression (primary endpoint), cystectomy, and duration of survival, taking into account age, concomitant carcinoma in situ, gender, multiplicity, tumor size, initial treatment, and tumor stage. Harrell's concordance (C-index) was used for prognostic accuracy of classification systems. RESULTS AND LIMITATIONS: The median age was 68 yr; 3292 (64%) patients had Ta tumors. Neither classification system was prognostic for recurrence. For a four-tier combination of both WHO systems, progression at 5-yr follow-up was 1.4% in low-grade (LG)/G1, 3.8% in LG/G2, 7.7% in high grade (HG)/G2, and 18.8% in HG/G3 (log-rank, p < 0.001). In multivariable analyses with WHO1973 and WHO2004/2016 as independent variables, WHO1973 was a significant prognosticator of progression (p < 0.001), whereas WHO2004/2016 was not anymore (p = 0.067). C-indices for WHO1973, WHO2004, and the WHO systems combined for progression were 0.71, 0.67, and 0.73, respectively. Prognostic analyses for cystectomy and survival showed results similar to those for progression. CONCLUSIONS: In this large prognostic factor study, both classification systems were prognostic for progression but not for recurrence. For progression, the prognostic value of WHO1973 was higher than that of WHO 2004/2016. The four-tier combination (LG/G1, LG/G2, HG/G2, and HG/G3) of both WHO systems proved to be superior, as it d

Published
2021

37. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel

Author

Sylvester, R.J., Rodríguez, O., Hernández, V., Turturica, D., Bauerová, L., Bruins, H.M., Bründl, J., Kwast, Theodorus H. van der, Brisuda, A., Rubio-Briones, J., Seles, M., Hentschel, A.E., Kusuma, V.R.M., Huebner, N., Cotte, J., Mertens, L.S., Volanis, D., Cussenot, O., Henríquez, J.D. Subiela, Peña, E. de la, Pisano, F., Pešl, M., Heijden, A.G. van der, Herdegen, S., Zlotta, A.R., Hacek, J., Calatrava, A., Mannweiler, S., Bosschieter, J., Ashabere, D., Haitel, A., Côté, J.F., Sheikh, S., Lunelli, L., Algaba, F., Alemany, I., Soria, F., Runneboom, W., Breyer, J., Nieuwenhuijzen, J.A., Llorente, C., Molinaro, L., Hulsbergen-van de Kaa, C.A., Evert, M., Kiemeney, L.A., N'Dow, J., Plass, K., Čapoun, O., Soukup, V., Dominguez-Escrig, J.L., Cohen, D., Palou, J., Gontero, P., Burger, M., Zigeuner, R., Mostafid, A.H., Shariat, S.F., Rouprêt, M., Compérat, E.M., Babjuk, M., Rhijn, B.W. van, Sylvester, R.J., Rodríguez, O., Hernández, V., Turturica, D., Bauerová, L., Bruins, H.M., Bründl, J., Kwast, Theodorus H. van der, Brisuda, A., Rubio-Briones, J., Seles, M., Hentschel, A.E., Kusuma, V.R.M., Huebner, N., Cotte, J., Mertens, L.S., Volanis, D., Cussenot, O., Henríquez, J.D. Subiela, Peña, E. de la, Pisano, F., Pešl, M., Heijden, A.G. van der, Herdegen, S., Zlotta, A.R., Hacek, J., Calatrava, A., Mannweiler, S., Bosschieter, J., Ashabere, D., Haitel, A., Côté, J.F., Sheikh, S., Lunelli, L., Algaba, F., Alemany, I., Soria, F., Runneboom, W., Breyer, J., Nieuwenhuijzen, J.A., Llorente, C., Molinaro, L., Hulsbergen-van de Kaa, C.A., Evert, M., Kiemeney, L.A., N'Dow, J., Plass, K., Čapoun, O., Soukup, V., Dominguez-Escrig, J.L., Cohen, D., Palou, J., Gontero, P., Burger, M., Zigeuner, R., Mostafid, A.H., Shariat, S.F., Rouprêt, M., Compérat, E.M., Babjuk, M., and Rhijn, B.W. van

Abstract

Item does not contain fulltext, BACKGROUND: The European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) are used to provide recommendations for patient treatment after transurethral resection of bladder tumor (TURBT). They do not, however, take into account the widely used World Health Organization (WHO) 2004/2016 grading classification and are based on patients treated in the 1980s. OBJECTIVE: To update EAU prognostic factor risk groups using the WHO 1973 and 2004/2016 grading classifications and identify patients with the lowest and highest probabilities of progression. DESIGN, SETTING, AND PARTICIPANTS: Individual patient data for primary NMIBC patients were collected from the institutions of the members of the EAU NMIBC guidelines panel. INTERVENTION: Patients underwent TURBT followed by intravesical instillations at the physician's discretion. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Multivariable Cox proportional-hazards regression models were fitted to the primary endpoint, the time to progression to muscle-invasive disease or distant metastases. Patients were divided into four risk groups: low-, intermediate-, high-, and a new, very high-risk group. The probabilities of progression were estimated using Kaplan-Meier curves. RESULTS AND LIMITATIONS: A total of 3401 patients treated with TURBT ± intravesical chemotherapy were included. From the multivariable analyses, tumor stage, WHO 1973/2004-2016 grade, concomitant carcinoma in situ, number of tumors, tumor size, and age were used to form four risk groups for which the probability of progression at 5 yr varied from <1% to >40%. Limitations include the retrospective collection of data and the lack of central pathology review. CONCLUSIONS: This study provides updated EAU prognostic factor risk groups that can be used to inform patient treatment and follow-up. Incorporating the WHO 2004/2016 and 1973 grading classifications, a new, very high-risk group has been identified for wh

Published
2021

38. Testicular Synthesis and Vitamin D Action

Author

Hofer, D., Münzker, J., Schwetz, V., Ulbing, M., Hutz, K., Stiegler, Ph., Zigeuner, R., Pieber, T. R., Müller, H., and Obermayer-Pietsch, B.

Published
2014

40. Hilfestellung zur sinnvollen Indikation der Metastasektomie bei metachron metastasierten Nierenzellkarzinompatienten

Author

Seles, M., Maisel, F., Smolle, M. A., Molnar, S., Riedl, J. M., Barth, D., Terbuch, A., Rossmann, C. H., Mannweiler, S., Hutterer, G. C., Zigeuner, R., Pummer, K., Smolle-Jüttner, F.-M., Lindenmann, J., Stotz, M., Gerger, A., Stöger, H., Pichler, M., and Posch, F.

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung: Die Metastasektomie stellt ein mögliches Verfahren in der Behandlungskaskade des metastasierten Nierenzellkarzinoms als Alternative zu systemischen Therapien wie Checkpoint- und/oder Tyrosinkinaseinhibitoren dar. Diese Behandlungsoption kann Patienten mitunter lang andauernde Remissionen[zum vollständigen Text gelangen Sie über die oben angegebene URL], 46. Gemeinsame Tagung der Bayerischen Urologenvereinigung und der Österreichischen Gesellschaft für Urologie und Andrologie

Published
2020

42. Corrigendum to ‘EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees’ [European Urology 77 (2020) 223–250](S0302283819307638)(10.1016/j.eururo.2019.09.035)

Author

Witjes, J.A. Babjuk, M. Bellmunt, J. Bruins, H.M. De Reijke, T.M. De Santis, M. Gillessen, S. James, N. Maclennan, S. Palou, J. Powles, T. Ribal, M.J. Shariat, S.F. Van Der Kwast, T. Xylinas, E. Agarwal, N. Arends, T. Bamias, A. Birtle, A. Black, P.C. Bochner, B.H. Bolla, M. Boormans, J.L. Bossi, A. Briganti, A. Brummelhuis, I. Burger, M. Castellano, D. Cathomas, R. Chiti, A. Choudhury, A. Compérat, E. Crabb, S. Culine, S. De Bari, B. De Blok, W. De Visschere, P.J.L. Decaestecker, K. Dimitropoulos, K. Dominguez-Escrig, J.L. Fanti, S. Fonteyne, V. Frydenberg, M. Futterer, J.J. Gakis, G. Geavlete, B. Gontero, P. Grubmüller, B. Hafeez, S. Hansel, D.E. Hartmann, A. Hayne, D. Henry, A.M. Hernandez, V. Herr, H. Herrmann, K. Hoskin, P. Huguet, J. Jereczek-Fossa, B.A. Jones, R. Kamat, A.M. Khoo, V. Kiltie, A.E. Krege, S. Ladoire, S. Lara, P.C. Leliveld, A. Linares-Espinós, E. Løgager, V. Lorch, A. Loriot, Y. Meijer, R. Mir, M.C. Moschini, M. Mostafid, H. Müller, A.-C. Müller, C.R. N'Dow, J. Necchi, A. Neuzillet, Y. Oddens, J.R. Oldenburg, J. Osanto, S. Oyen, W.J.G. Pacheco-Figueiredo, L. Pappot, H. Patel, M.I. Pieters, B.R. Plass, K. Remzi, M. Retz, M. Richenberg, J. Rink, M. Roghmann, F. Rosenberg, J.E. Rouprêt, M. Rouvière, O. Salembier, C. Salminen, A. Sargos, P. Sengupta, S. Sherif, A. Smeenk, R.J. Smits, A. Stenzl, A. Thalmann, G.N. Tombal, B. Turkbey, B. Lauridsen, S.V. Valdagni, R. Van Der Heijden, A.G. Van Poppel, H. Vartolomei, M.D. Veskimäe, E. Vilaseca, A. Rivera, F.A.V. Wiegel, T. Wiklund, P. Willemse, P.-P.M. Williams, A. Zigeuner, R. Horwich, A.

Abstract

The authors regret that a co-author was mistakenly missed from the authorship. The following co-author should have been included in the authorship: Peter-Paul M. Willemse Department of Oncological Urology, University Medical Center, Utrecht Cancer Center, Utrecht, The Netherlands © 2019 European Society of Medical Oncology and European Association of Urology

Published
2020

43. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees

Author

Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Der Kwast TV, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, De Bari B, De Blok W, J L De Visschere P, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Müller AC, Müller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, J G Oyen W, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Van Der Heijden AG, Van Poppel H, Vartolomei MD, Veskimäe E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Zigeuner R, Horwich A.

Subjects
Consensus, Follow-up, education, Bladder cancer, Diagnosis, Treatment, Delphi
Abstract

Background: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. Objective: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. Design: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts prior to voting during a consensus conference. Setting: Online Delphi survey and consensus conference. Participants: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. Outcome measurements and statistical analysis: Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), and 7-9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). Results and limitations: Overall, 116 statements were included in the Delphi survey. Of these statements, 33 (28%) achieved level 1 consensus and 49 (42%) achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease, and the evolving role of checkpoint inhibitor therapy in metastatic disease. Conclusions: These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time when further evidence is available to guide our approach. Patient summary: This report summarises findings from an international, multistakeholder project organised by the EAU and ESMO. In this project, a steering committee identified areas of bladder cancer management where there is currently no good-quality evidence to guide treatment decisions. From this, they developed a series of proposed statements, 71 of which achieved consensus by a large group of experts in the field of bladder cancer. It is anticipated that these statements will provide further guidance to health care professionals and could help improve patient outcomes until a time when good-quality evidence is available.

Published
2020

45. Hilfestellung zur sinnvollen Indikation der Metastasektomie bei metachron metastasierten Nierenzellkarzinompatienten

Author

Seles, M, Maisel, F, Smolle, MA, Molnar, S, Riedl, JM, Barth, D, Terbuch, A, Rossmann, CH, Mannweiler, S, Hutterer, GC, Zigeuner, R, Pummer, K, Smolle-Jüttner, FM, Lindenmann, J, Stotz, M, Gerger, A, Stöger, H, Pichler, M, Posch, F, Seles, M, Maisel, F, Smolle, MA, Molnar, S, Riedl, JM, Barth, D, Terbuch, A, Rossmann, CH, Mannweiler, S, Hutterer, GC, Zigeuner, R, Pummer, K, Smolle-Jüttner, FM, Lindenmann, J, Stotz, M, Gerger, A, Stöger, H, Pichler, M, and Posch, F

Published
2020

46. Transurethral Resection of Bladder Tumour: The Neglected Procedure in the Technology Race in Bladder Cancer

Author

Mostafid, H, Babjuk, M., Bochner, B., Lerner, S.P., Witjes, F., Palou, J., Roupret, M., Shariat, S., Gontero, P., van Rhijn, B., Zigeuner, R., Sylvester, R., Comperat, E., Burger, M., Malavaud, B., Soloway, M., Williams, S., Black, P., Daneshmand, S., Steinberg, G., Brausi, M., Catto, J., Kamat, A.M., Mostafid, H, Babjuk, M., Bochner, B., Lerner, S.P., Witjes, F., Palou, J., Roupret, M., Shariat, S., Gontero, P., van Rhijn, B., Zigeuner, R., Sylvester, R., Comperat, E., Burger, M., Malavaud, B., Soloway, M., Williams, S., Black, P., Daneshmand, S., Steinberg, G., Brausi, M., Catto, J., and Kamat, A.M.

Abstract

Contains fulltext : 220581.pdf (Publisher’s version ) (Closed access), Transurethral resection of bladder tumour is the initial, most critical step in the management of bladder cancer; as such, this is a call to arms for the urological community to it the due diligence it deserves regarding technology and training.

Published
2020

48. P119 - Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, non-invasive bladder tumors in 2019?

Author

Hentschel, A.E., Van Rhijn, B.W.G., Bründl, J., Compérat, E.M., Plass, K., Rodríguez, O., Subiela Henríquez, J.D., Hernández, V., De La Peña, E., Alemany, I., Turturica, D., Pisano, F., Soria, F., Čapoun, O., Bauerová, L., Pešl, M., Bruins, H.M., Runneboom, W., Herdegen, S., Breyer, J., Brisuda, A., Scavarda-Lamberti, A., Calatrava, A., Rubio-Briones, J., Seles, M., Mannweiler, S., Bosschieter, J., Kusuma, V.R.M., Ashabere, D., Huebner, N., Cotte, J., Mertens, L.S., Cohen, D., Lunelli, L., Cussenot, O., El Sheikh, S., Volanis, D., Coté, J.F., Rouprêt, M., Haitel, A., Shariat, S.F., Mostafid, A.H., Nieuwenhuijzen, J.A., Zigeuner, R., Dominguez-Escrig, J.L., Hacek, J., Zlotta, A.R., Burger, M., Evert, M., Hulsbergen - Van De Kaa, C.A., Van Der Heijden, A.G., Kiemeney, L.A.L.M., Soukup, V., Molinaro, L., Gontero, P., Llorente, C., Algaba, F., Palou, J., N’dow, J., Babjuk, M., Van Der Kwast, T.H., and Sylvester, R.J.

Published
2019
Full Text
View/download PDF

49. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-2019 Update

Author

Babjuk, M, Burger, M, Comperat, EM, Gontero, P, Mostafid, AH, Palou, J, van Rhijn, BWG, Roupret, M, Shariat, SF, Sylvester, R, Zigeuner, R, Capoun, O, Cohen, D, Escrig, JLD, Hernandez, V, Peyronnet, B, Seisen, T, and Soukup, V

Subjects
Radical cystectomy, Follow-up, Transurethral resection, Bladder cancer, Diagnosis, European association of urology, Urothelial carcinoma, Cystoscopy, Guidelines, Prognosis, unresponsive, Bacillus Calmette-Guerin, Intravesical chemotherapy
Abstract

Context: This overview presents the updated European Association of Urology (EAU) guidelines for non-muscle-invasive bladder cancer (NMIBC), TaT1, and carcinoma in situ (CIS). Objective: To provide practical recommendations on the clinical management of NMIBC with a focus on clinical presentation and recommendations. Evidence acquisition: A broad and comprehensive scoping exercise covering all areas of the NMIBC guidelines has been performed annually since the last published version in 2017. Databases covered by the search included Medline, EMBASE, and the Cochrane Libraries. Previous guidelines were updated, and the level of evidence and grade of recommendation were assigned. Evidence synthesis: Tumours staged as Ta, T1, and/or CIS are grouped under the heading of NMIBC. Diagnosis depends on cystoscopy and histological evaluation of the tissue obtained by transurethral resection (TURB) in papillary tumours or by multiple bladder biopsies in CIS. In papillary lesions, a complete TURB is essential for the patient's prognosis and correct diagnosis. Where the initial resection is incomplete, where there is no muscle in the specimen, or where a T1 tumour is detected, a second TURB should be performed within 2-6 wk. The risks of both recurrence and progression may be estimated for individual patients using the European Organisation for Research and Treatment of Cancer (EORTC) scoring system. Stratification of patients into low-, intermediate-, and high-risk groups is pivotal to the recommendation of adjuvant treatment. In patients with tumours presumed to be at a low risk and in those presumed to be at an intermediate risk with a low previous recurrence rate and an expected EORTC recurrence score of

Published
2019

50. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees

Author

Horwich, A. Babjuk, M. Bellmunt, J. Bruins, H.M. De Reijke, T.M. De Santis, M. Gillessen, S. James, N. Maclennan, S. Palou, J. Powles, T. Ribal, M.J. Shariat, S.F. Van Der Kwast, T. Xylinas, E. Agarwal, N. Arends, T. Bamias, A. Birtle, A. Black, P.C. Bochner, B.H. Bolla, M. Boormans, J.L. Bossi, A. Briganti, A. Brummelhuis, I. Burger, M. Castellano, D. Cathomas, R. Chiti, A. Choudhury, A. Compérat, E. Crabb, S. Culine, S. De Bari, B. DeBlok, W. De Visschere, P.J.L. Decaestecker, K. Dimitropoulos, K. Dominguez-Escrig, J.L. Fanti, S. Fonteyne, V. Frydenberg, M. Futterer, J.J. Gakis, G. Geavlete, B. Gontero, P. Grubmüller, B. Hafeez, S. Hansel, D.E. Hartmann, A. Hayne, D. Henry, A.M. Hernandez, V. Herr, H. Herrmann, K. Hoskin, P. Huguet, J. Jereczek-Fossa, B.A. Jones, R. Kamat, A.M. Khoo, V. Kiltie, A.E. Krege, S. Ladoire, S. Lara, P.C. Leliveld, A. Linares-Espinós, E. Løgager, V. Lorch, A. Loriot, Y. Meijer, R. Carmen Mir, M. Moschini, M. Mostafid, H. Müller, A.-C. Müller, C.R. N'Dow, J. Necchi, A. Neuzillet, Y. Oddens, J.R. Oldenburg, J. Osanto, S. Oyen, W.J.G. Pacheco-Figueiredo, L. Pappot, H. Patel, M.I. Pieters, B.R. Plass, K. Remzi, M. Retz, M. Richenberg, J. Rink, M. Roghmann, F. Rosenberg, J.E. Rouprêt, M. Rouvière, O. Salembier, C. Salminen, A. Sargos, P. Sengupta, S. Sherif, A. Smeenk, R.J. Smits, A. Stenzl, A. Thalmann, G.N. Tombal, B. Turkbey, B. Vahr Lauridsen, S. Valdagni, R. Van Der Heijden, A.G. Van Poppel, H. Vartolomei, M.D. Veskimäe, E. Vilaseca, A. Vives Rivera, F.A. Wiegel, T. Wiklund, P. Williams, A. Zigeuner, R. Witjes, J.A.

Subjects
education
Abstract

Background: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. Objective: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. Design: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts before voting during a consensus conference. Setting: Online Delphi survey and consensus conference. Participants: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. Outcome measurements and statistical analysis: Statements were ranked by experts according to their level of agreement: 1–3 (disagree), 4–6 (equivocal), 7–9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). Results and limitations: Overall, 116 statements were included in the Delphi survey. Of these, 33 (28%) statements achieved level 1 consensus and 49 (42%) statements achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease and the evolving role of checkpoint inhibitor therapy in metastatic disease. Conclusions: These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time where further evidence is available to guide our approach. © 2019 European Society for Medical Oncology

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results